Heparin prevents programmed cell death in human trophoblast
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Heparin is used clinically for the prevention of pregnancy complications associated with prothrombotic disorders, especially antiphospholipid antibody syndrome. Recent studies have suggested that heparin may exert direct effects on placental trophoblast, independently of its anticoagulant activity. We now demonstrate that heparin abrogates apoptosis of primary first trimester villous trophoblast in response to treatment with the pro-inflammatory cytokines interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha. This multifunctional glycosaminoglycan also inhibited apoptosis induced by other agents, including staurosporin, broad-spectrum kinase inhibitor and thrombin. Furthermore, heparin attenuated caspase-3 activity, a hallmark of apoptosis, in human first trimester villous and extravillous trophoblast cell lines treated with peptidoglycan, a Toll-like receptor-2 agonist isolated from Staphylococcus aureus. The ability of heparin to antagonize cell death induced by such diverse apoptotic signals suggested that it acts as a survival factor for human trophoblast. We demonstrate that heparin, like epidermal growth factor (EGF) and heparin-binding EGF (HB-EGF), elicits phosphorylation of the EGF receptor and activation of the phosphatidyl inositol 3-kinase (PI3K)-, the extracellular signal-related kinase 1/2 (ERK1/2)- and the c-Jun NH2 terminal kinase (JNK)-signal transduction pathways in primary villous trophoblast. In summary, we have demonstrated that heparin activates multiple anti-apoptotic pathways in human trophoblast. Our results suggest that heparin may be useful in the management of at-risk patients, even in the absence of an identifiable thrombophilic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rai, R., Cohen, H., Dave, M., & Regan, L. (1997) · BMJ · doi:10.1136/bmj.314.7076.253 · Cited by 1,113
Self-citationThrombophilic disorders and fetal loss: a meta-analysis
Rey, E., Kahn, S. R., David, M., & Shrier, I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12771-7 · Cited by 872
Increased placental apoptosis in pregnancies complicated by preeclampsia
Leung, D. N., Smith, S. C., To, K. F., Sahota, D. S., & Baker, P. N. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.112906 · Cited by 281
Cited by
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Bates, S. M., Greer, I. A., Middeldorp, S., Veenstra, D. L., Prabulos, A.-M., & Vandvik, P. O. (2012) · Chest · doi:10.1378/chest.11-2300 · Cited by 1,525
Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Bates, S. M., Greer, I. A., Pabinger, I., Sofaer, S., & Hirsh, J. (2008) · Chest · doi:10.1378/chest.08-0761 · Cited by 793
Silica and titanium dioxide nanoparticles cause pregnancy complications in mice
Yamashita, K., Yoshioka, Y., Higashisaka, K., Mimura, K., Morishita, Y., Nozaki, M., Yoshida, T., Ogura, T., Nabeshi, H., Nagano, K., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.41 · Cited by 738
Clark, P., Walker, I. D., Langhorne, P., Crichton, L., Thomson, A., Greaves, M., Whyte, S., & Greer, I. A. (2010) · Blood · doi:10.1182/blood-2010-01-267252 · Cited by 257
New Applications of Heparin and Other Glycosaminoglycans
Lima, M., Rudd, T., & Yates, E. (2017) · Molecules · doi:10.3390/molecules22050749 · Cited by 89
Kleppa, M.-J., Erlenwein, S.-V., Darashchonak, N., von Kaisenberg, C. S., & von Versen-Höynck, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099217 · Cited by 8
Metadata
- Authors
- Hills, F. A., Abrahams, V. M., Gonzalez-Timon, B., Francis, J., Cloke, B., Hinkson, L., Rai, R., Mor, G., Regan, L., Sullivan, M., Lam, E. W.-F., & Brosens, J. J.
- Venue
- Molecular Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-03-23
- Volume
- 12
- Issue
- 4
- Pages
- 237-243
- ISSN
- 1360-9947 (ISSN-L)
- 1460-2407
- OpenAlex
- W2096465727
- Cited by
- 124
- References
- 3
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.